Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Phospholipid drug conjugate therapies

Jarrod Longcor • 28 Sep 2019
ESMO 2019
General

Jarrod Longcor, MA, MBA, Cellectar Biosciences, Madison, WI, outlines the current focus on phospholipid drug conjugate (PDCs), specifically CLR131, and what the future holds for this line of therapy at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Jarrod Longcor

R/R DLBCL challanges: novel therapeutics
1:15
R/R DLBCL challanges: novel therapeutics
Jarrod Longcor • 28 Sep 2019
Jarrod Longcor: ESMO highlights
1:22
Jarrod Longcor: ESMO highlights
Jarrod Longcor • 28 Sep 2019

Related Videos

Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI in clinical decision-making
2:25
Addressing the risk of over-reliance on AI in clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026
Telomere dynamics in normal and pathological aging
12:41
Telomere dynamics in normal and pathological aging
Coleman Lindsley • 18 Sep 2026
The content of VJHemOnc is intended for healthcare professionals